{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:15:26Z","timestamp":1790187326300,"version":"4.1.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint blockade (ICB) has indeed transformed the outlook for many advanced-stage solid tumors, yet its effectiveness in hematological malignancies has been particularly limited, with success predominantly demonstrated in classical Hodgkin lymphoma (cHL) and immune-privilege subtypes of non-Hodgkin lymphoma (NHL). In this report, we present an impactful case of a 71-year-old man grappling with refractory follicular lymphoma (rFL) that had progressed to a high-grade lymphoma, leaving no conventional treatment options on the table. Notably, the histological examination of the tumor tissue revealed a markedly elevated PD-L1 expression, illuminating the potential for immunotherapy to be effective. Additionally, comprehensive gene sequencing unveiled a moderate tumor mutational burden (TMB), deepening our understanding of the tumor\u2019s molecular intricacies. As his health declined with no access to cell therapies or clinical trials at that time, a combination treatment of PD-1 ICB and an anti-CD20 drug surprisingly led to a significant improvement in his condition and long-term remission. While PD-1 ICB therapy has historically shown limited responses in non-Hodgkin lymphomas (NHLs), this case serves as a beacon of optimism, underscoring the promise of combining immunotherapy modalities and the potential of comprehensive molecular assessments in charting innovative treatments for extensively treated NHL patients. The quest for predictive biomarkers to gauge treatment response remains a formidable challenge. This report serves as a testament to the ever-evolving landscape of cancer treatment, where precision medicine and immunotherapy continue to unlock new possibilities for those confronting the most challenging malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2024.1308492","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T05:35:49Z","timestamp":1709184949000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: From sequence to solution: tailoring treatment for transformed follicular lymphoma (DLBCL) through next generation sequencing study"],"prefix":"10.3389","volume":"14","author":[{"given":"Antonin","family":"Bouroumeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Perdikis-Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"","journal-title":"JCO"},{"key":"B3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.annonc.2020.11.008","article-title":"Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dreyling","year":"","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01251-z","article-title":"Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas","volume":"35","author":"H\u00fcbschmann","year":"","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18974","article-title":"Integrative genomic and transcriptomic analysis reveals genetic alterations associated with the early progression of follicular lymphoma","author":"Gao","year":"202","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"","journal-title":"J immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11061720","article-title":"Efficacy of immune checkpoint blockade and biomarkers of response in lymphoma: A narrative review","volume":"11","author":"Perdikis-Prati","year":"","journal-title":"Biomedicines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123908","article-title":"Immune priming with single-agent nivolumab followed by combined Nivolumab & Rituximab is safe and efficacious for first-line treatment of follicular lymphoma; interim analysis of the \u20181st FLOR\u2019 Study","volume":"134","author":"Barraclough","year":"","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7560","article-title":"Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study","volume":"39","author":"Hawkes","year":"","journal-title":"JCO"},{"key":"B13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V130.Suppl_1.481.481","article-title":"Safety and efficacy of atezolizumab in combination with obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma: an interim analysis","volume":"130","author":"Younes","year":"2017","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-116678","article-title":"Safety and efficacy of Atezolizumab in combination with rituximab plus CHOP in previously untreated patients with diffuse large B-cell lymphoma (DLBCL): primary analysis of a phase I\/II study","volume":"132","author":"Younes","year":"","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.59.59","article-title":"Nivolumab combined with ibrutinib for CLL and richter transformation: A phase II trial","volume":"128","author":"Jain","year":"","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-120355","article-title":"A phase II trial of nivolumab combined with ibrutinib for patients with richter transformation","volume":"132","author":"Jain","year":"","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ajh.25659","article-title":"Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma","volume":"95","author":"Herrera","year":"","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study","volume":"37","author":"Ansell","year":"","journal-title":"JCO"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000784","article-title":"PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation","volume":"4","author":"Frigault","year":"","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-021-03241-4","article-title":"Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial","volume":"115","author":"Nowakowski","year":"","journal-title":"Int J Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386","article-title":"Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers","volume":"16","author":"Goodman","year":"","journal-title":"Mol Cancer Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"","journal-title":"Genome Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0903","article-title":"Mutational landscape and sensitivity to immune checkpoint blockers","volume":"22","author":"Chabanon","year":"","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/1179554920976366","article-title":"Predicting responses to checkpoint inhibitors in lymphoma: are we up to the standards of solid tumors","volume":"14","author":"Jeong","year":"","journal-title":"Clin Med Insights Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1308492\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T05:35:53Z","timestamp":1709184953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1308492\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":28,"alternative-id":["10.3389\/fonc.2024.1308492"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1308492","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]},"article-number":"1308492"}}